Compare SYK & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYK | BMY |
|---|---|---|
| Founded | 1941 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.2B | 111.3B |
| IPO Year | N/A | N/A |
| Metric | SYK | BMY |
|---|---|---|
| Price | $355.28 | $54.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $432.13 | $56.31 |
| AVG Volume (30 Days) | 1.7M | ★ 16.9M |
| Earning Date | 01-27-2026 | 02-05-2026 |
| Dividend Yield | 0.99% | ★ 4.64% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.61 | 2.97 |
| Revenue | $24,381,000,000.00 | ★ $48,034,000,000.00 |
| Revenue This Year | $11.98 | $0.23 |
| Revenue Next Year | $8.60 | N/A |
| P/E Ratio | $46.62 | ★ $18.27 |
| Revenue Growth | ★ 10.95 | 1.26 |
| 52 Week Low | $329.16 | $42.52 |
| 52 Week High | $406.19 | $63.33 |
| Indicator | SYK | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 69.74 |
| Support Level | $349.55 | $54.01 |
| Resistance Level | $359.81 | $54.86 |
| Average True Range (ATR) | 6.01 | 1.07 |
| MACD | 0.17 | 0.10 |
| Stochastic Oscillator | 35.65 | 96.91 |
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.